Recent Posts

jCyte Receives Regenerative Medicine Advanced Therapy Designation May 2, 2017 - May 2, 2017 – Cell therapy company jCyte announced that the U.S. Food & Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for the company’s developmental retinitis pigmentosa (RP) treatment, jCell. RMAT seeks Read More >
Powered by CIRM Grant, jCyte Launches New Clinical Trial April 19, 2017 - Phase 2b study will investigate safety and efficacy of retinitis pigmentosa therapy   April 19, 2017 – Cell therapy company jCyte is launching a phase 2b clinical trial to test the safety and efficacy of Read More >
Retinitis Pigmentosa Therapy Highlighted at CIRM Symposium April 3, 2017 - The California Institute for Regenerative Medcine's (CIRM's) second annual Alpha Stem Cell Clinics Network symposium showcased how stem cell therapies are rapidly moving towards the clinic. One of our co-founders, Dr. Henry Klassen, spoke about Read More >